P-Glycoprotein Modulation Improves in Vitro Chemosensitivity in Malignant Pediatric Liver Tumors

Anticancer Research

Volumn 23, Issue 6 C, 2003, Pages 4607-4611

  Warmann, Steven ^a,b   Göhring, Gudrun ^b   Teichmann, Birgit ^b   Geerlings, Heinz ^b   Pietsch, Torsten ^c   Fuchs, Jörg ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Chemosensitizer; Hepatocellular carcinoma; Human hepatoblastoma; Multidrug resistance; P glycoprotein

Indexed keywords

CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ACRIDINES; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CHILD; CISPLATIN; CYCLOSPORINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; P-GLYCOPROTEIN; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0842311702     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Brown J, Perilongo O, Shafford E et al: Pretreatment prognostic factors for children with hepatoblastoma-results from the International Society of Pediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 36: 1418-1425, 2000.
2. Fuchs J, Rydzynski J, von Schweinitz D et al: Pretreatment prognostic factors and treatment results in children with hepatoblastoma - a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 95: 172-182, 2002.
3. Czauderna P, Mackinlay G, Perilongo G et al: Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology Group. J Clin Oncol 20: 2798-2804, 2002.
4. Von Schweinitz D, Hecker H and Harms D: Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma. J Pediatr Surg 30: 845-852, 1995.
5. Minemura M, Tanimura H and Tabor E: Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 15: 559-563, 1999.
6. Bader P, Fuchs J, Wenderoth M et al: Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with doxorubicin or cisplatin. Anticancer Res 18: 3127-3132, 1998.
7. Goldstein LJ, Galski H, Fojo A et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
8. Fisher GA, Lum BL, Hausdorff J and Sikic BI: Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32: 1082-1088, 1996.
9. Warmann S, Hunger M, Teichmann B et al: The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma-clinical course and in vivo model. Cancer 95: 1795-1801, 2002.
10. Warmann S, Göhring G, Teichmann B et al: MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro. J Pediatr Surg 37: 1579-1584, 2002.
11. Ortega JA, Douglass EC, Feusner JH et al: Randomized comparison of cisplatin/vincristine/floururacil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18: 2665-2675, 2000.
12. Pietsch T, Fonatsch C, Albrecht S et al: Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74: 809-817 1996.
13. Doi I: Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 67: 1-10, 1976.
14. Aden D, Fogel A, Plotkin S et al: Controlled synthesis of HbsAg in a differentiated human liver carcinoma-derived cell line. Nature 282: 615-617, 1979.
15. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
16. Scheffé H: The Analysis of Variance. New York, 1959.
17. Dawson-Saunders B and Trapp RE: Basic and Clinical Biostatistics. Apleton and Lange, 1994.
18. Von Schweinitz D, Byrd D, Hecker H et al: Efficiency and toxocity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Eur J Cancer 33: 1243-1249, 1997.
19. Watanabe T, Tsuge H, Oh-Hara T et al: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 2: 235-241, 1995.
20. Pu YS, Hsieh TS, Tsai TC et al: Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol 154: 601-605, 1995.
21. Baekelandt M, Lehne G, Trope CG et al: Phase I/II trial of the multidrug resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 19: 2983-2993, 2001.